{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Radiation+therapy+-+1+week&page=2", "query": { "intervention": "Radiation therapy - 1 week", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 2114, "total_pages": 212, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Radiation+therapy+-+1+week&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Radiation+therapy+-+1+week&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-01T11:32:44.451Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02057107", "title": "SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Previously-Irradiated", "Squamous Cell Carcinoma of the Head and Neck Cancer" ], "interventions": [ { "name": "SBRT", "type": "RADIATION" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Heath Skinner", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2013-07-03", "completion_date": "2019-12-31", "has_results": false, "last_update_posted_date": "2023-06-05", "last_synced_at": "2026-10-01T11:32:44.451Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02057107" }, { "nct_id": "NCT00109837", "title": "S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "daunorubicin", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "mercaptopurine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "mitoxantrone", "type": "DRUG" }, { "name": "Asparaginase", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "thioguanine", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "allopurinol", "type": "DRUG" }, { "name": "bactrim", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 79, "start_date": "2005-04", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2015-03-25", "last_synced_at": "2026-10-01T11:32:44.451Z", "location_count": 78, "location_summary": "Burbank, California • Maywood, Illinois • Chanute, Kansas + 45 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Chanute", "state": "Kansas" }, { "city": "Dodge City", "state": "Kansas" }, { "city": "El Dorado", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00109837" }, { "nct_id": "NCT02313272", "title": "Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Glioma" ], "interventions": [ { "name": "Hypofractionated Stereotactic Irradiation (HFSRT)", "type": "RADIATION" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2015-07-28", "completion_date": "2021-08-09", "has_results": true, "last_update_posted_date": "2023-10-23", "last_synced_at": "2026-10-01T11:32:44.451Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02313272" }, { "nct_id": "NCT04013672", "title": "Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Glioblastoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "SurVaxM", "type": "DRUG" }, { "name": "Sargramostim", "type": "DRUG" }, { "name": "Montanide ISA 51", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David Peereboom", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2020-03-19", "completion_date": "2022-02-16", "has_results": true, "last_update_posted_date": "2024-08-28", "last_synced_at": "2026-10-01T11:32:44.451Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04013672" }, { "nct_id": "NCT05169957", "title": "Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma, Ocular", "Melanoma, Cutaneous", "Metastatic Melanoma", "Melanoma, Mucosal", "Liver Metastases" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Stereotactic Body Radiation Therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2022-08-09", "completion_date": "2024-07-17", "has_results": false, "last_update_posted_date": "2024-11-05", "last_synced_at": "2026-10-01T11:32:44.451Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05169957" }, { "nct_id": "NCT00002569", "title": "Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "lomustine", "type": "DRUG" }, { "name": "procarbazine hydrochloride", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 299, "start_date": "1994-07", "completion_date": "2018-05-21", "has_results": false, "last_update_posted_date": "2018-06-18", "last_synced_at": "2026-10-01T11:32:44.451Z", "location_count": 95, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002569" }, { "nct_id": "NCT00206466", "title": "Biologic Correlative Taxotere/AC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Taxotere", "type": "DRUG" }, { "name": "Adriamycin/cytoxan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor Breast Care Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 70, "start_date": "2002-04", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2012-01-25", "last_synced_at": "2026-10-01T11:32:44.451Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00206466" }, { "nct_id": "NCT00513383", "title": "Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Panitumumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Intensity Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2006-04", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2017-03-01", "last_synced_at": "2026-10-01T11:32:44.451Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00513383" }, { "nct_id": "NCT04601831", "title": "'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Focal radiation therapy (RT)", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2020-12-23", "completion_date": "2025-05-27", "has_results": false, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-10-01T11:32:44.451Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04601831" }, { "nct_id": "NCT02584829", "title": "Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Merkel Cell Polyomavirus Infection", "Stage IV Merkel Cell Carcinoma AJCC v7" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells", "type": "BIOLOGICAL" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Recombinant Interferon Beta", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2015-11-06", "completion_date": "2018-12-18", "has_results": true, "last_update_posted_date": "2022-03-22", "last_synced_at": "2026-10-01T11:32:44.451Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02584829" } ] }